[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100650594":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":27,"responsibleParty":43,"collaborators":20,"id":45,"slug":46,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":20,"eligibilityCriteria":51,"healthyVolunteers":47,"sex":52,"minAge":53,"maxAge":20,"enrollmentInfo":54,"targetDuration":20,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":20,"overallStatus":30,"whyStopped":20,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},{"fullName":5,"class":6},"BrosMed Medical Co., Ltd","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Test group","EXPERIMENTAL","Thrombectomy system",[13],"Device: Peripheral thrombectomy system",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DEVICE","Peripheral thrombectomy system","For the subjects who met the requirements of the study protocol, the BM peripheral thrombectomy system was used for treatment.",[9],null,[22],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Fu, PhD","CONTACT","021-31587871","fu.weiguo@zs-hospital.sh.cn",[28],{"facility":29,"status":30,"city":31,"state":20,"zip":32,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"Zhongshan Hospital, Fudan University","RECRUITING","Shanghai","200032","China","CN",{"type":36,"coordinates":37},"Point",[38,39],121.45806,31.22222,{"lat":39,"lon":38},[42],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},{"type":44,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100650594","clinical-trial-of-thrombectomy-systems-100650594",false,"NCT07749820","Clinical Trial of Thrombectomy Systems","A Prospective, Multicenter, Single-Arm Clinical Trial Evaluating the Safety and Efficacy of Thrombectomy Systems for the Treatment of Lower Extremity Deep Vein Thrombosis","Inclusion Criteria:\n\n* Age ≥18 years；\n* Confirmed lower extremity deep vein thrombosis (DVT) by imaging, meeting at least one of the following: (1) acute iliofemoral or femoropopliteal DVT; or (2) subacute iliofemoral DVT;\n* Investigator-assessed life expectancy ≥1 year;\n* Willing to participate in this study and provide written informed consent.\n\nExclusion Criteria:\n\n* Infection at the puncture site or severe systemic infection;\n* Inability to establish vascular access or difficulty in advancing the guidewire through the lesion;\n* Hemodynamically unstable pulmonary embolism;\n* The target lesion thrombosis is recurrent after prior interventional therapy;\n* A venous stent has been implanted in the target lesion, or the presence of an inferior vena cava filter that interferes with device deployment;\n* Bilateral lower extremity deep vein thrombosis requiring thrombectomy in the same procedure;\n* Active bleeding within the past 30 days, including severe intracranial, gastrointestinal, or urinary tract bleeding;\n* History of hemorrhagic or ischemic stroke within the past 30 days;\n* Known severe coagulation disorder or bleeding tendency;\n* Severe hepatic or renal impairment;\n* Known allergy or significant hypersensitivity to iodine-based contrast media, thrombolytic agents, anticoagulants, or antiplatelet drugs;\n* Known conditions such as severe hyperthyroidism, multiple myeloma, or severe heart failure that preclude tolerance to percutaneous transluminal angioplasty;\n* Pregnant or lactating women, or women planning to become pregnant during the study period;\n* Currently participating in any other clinical trial of a drug or medical device;\n* Any other condition that, in the investigator's judgment, makes the subject ineligible for participation in this trial.","ALL","18 Years",{"count":55,"type":56},167,"ESTIMATED","INTERVENTIONAL",[59],"NA","This study plans to enroll 167 subjects. Subject enrollment and treatment details will be documented, and follow-up assessments will be conducted at screening, on the procedure day, before discharge, and at 1, 3, and 6 months after the procedure, to assess the safety and efficacy of the peripheral thrombectomy system for the treatment of lower extremity deep vein thrombosis.",[62],"Deep Vein Thrombosis (DVT)","2026-08-05",{"date":65,"type":66},"2026-08-07","ACTUAL",{"date":68,"type":56},"2026-08-30",{"date":70,"type":56},"2027-12-30",{"name":5,"class":6},1]